Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
This study will investigate the combination of Ytrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT) followed by Stereotactic Body Radiation Therapy (SBRT). Y-90 SIRT alone or SBRT alone are standard procedures used in the treatment of liver cancer. This study will assess the combination of Y-90 SIRT and SBRT and obtain preliminary information about the side effects and safety of the combination therapy. Additionally, this is the first time that Y-90 PET-CT imaging will be included in planning for SBRT.
Sponsor:
University of Michigan Rogel Cancer Center
Phase:
Phase 1
Contacts:
Cancer AnswerLinecanceranswerline@med.umich.edu
1-800-865-1125
Government Study Link:
NCT04518748 - Click here to see study onClinicalTrials.gov
Help us improve your experience